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The binding specificity and affinity of aptamers have long been harnessed as the key elements in the development of aptamer-
based assays, particularly aptasensing application. One promising avenue that is currently explored based on the specificity and
affinity of aptamers is the application of aptamers in the decontamination assays. Aptamers have been successfully harnessed
as the decontamination agents to remove contaminants from the environment and to decontaminate infectious elements. The
reversible denaturation property inherent in aptamers enables the repeated usage of aptamers, which can immensely save the cost of
decontamination. Analogous to the point-of-care diagnostics, there is no doubt that aptamers can also be deployed in the point-of-
care aptamer-based decontamination assay, whereby decontamination can be performed anywhere and anytime for instantaneous
decision-making. It is also prophesied that aptamers can also serve more than as a decontaminant, probably as a tool to capture
and kill hazardous elements, particularly pathogenic agents.
1. Introduction
Environmental contamination has been a major concern
worldwide for the past two centuries [1]. Major environmen-
tal contaminants are organic compounds such as small
organic and inorganic pollutants, pharmaceuticals, personal
care products, toxins of microbial origin, and pathogens [2–
5].These environmental contaminants have severe impact on
quality of food, air, and water, in turn exerting mild to severe
deadly effects on human and animals. A range of decontami-
nation methods have been devised to remove environmental
contaminants in contaminated soils, leachate, wastewater,
and infected tissues [6–8]. General strategies used for remov-
ing contaminants from contaminated environment include
chemical precipitation, ion exchange, reverse osmosis, and
solvent extraction [9]. A novel strategy that is worth ven-
turing into is to use aptamers to remove contaminants in
contaminated environments [10, 11].
Generated by Systematic Evolution of Ligands by Expo-
nential Enrichment (SELEX), aptamers are short synthetic
oligonucleotides, either DNA or RNA, that specifically
bind target molecule(s) with high specificity due to their
specific and complex three-dimensional shape comprised
stems, loops, bulges, hairpins, pseudoknots, triplexes, and
quadraplexes [12–14]. Aptamers are able to bind a wide
variety of targets from divalent metal ions, small organic
molecules, proteins, and cells [15, 16]. Binding specificity and
affinity of aptamers are harnessed in various applications,
majorly in biosensing applications [10, 11, 17–26]. Apart from
biosensing application, aptamers have also been the subject in
the aptamer-based capture assay. In the capture assay applica-
tions, aptamers are applied for the purification of their corre-
sponding targets for a wide variety of purposes [11, 27, 28].
The present review seeks to present an overview of the more
narrowed context of the aptamer-based capture assay, which
is on the usage of the aptamer in the decontaminating process
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or simply abbreviated as apta-decontamination assay. Several
aspects of the apta-decontamination assaywill be deliberated,
which encompasses the functionalization of the aptamer to
the usage of the aptamer in decontaminating environment,
food sample, and in in vivo application. Reusability of
the aptamer and the development of point-of-care apta-
decontamination assays are explored before envisaging the
potential future trend of the apta-decontamination assay.
2. Potentiation of the Apta-Decontamination
Assays Is Fueled by the Availability of a
Large Number of Small Molecule Aptamers
Most of the contaminants present in the environment are
small molecules [29]. Despite the technical challenges in
isolating aptamers against small molecules such as the target
immobilization and the determination of binding affini-
ties, a significant number of small molecule aptamers were
isolated. The availability of a myriad of small molecule
aptamers suggests that these aptamers can be used as the
corresponding decontaminating agents [28]. One important
property of the aptamer that substantiates its role as the
decontaminating agent is the exceptional discerning ability
of the aptamers even against small molecules. RNA aptamer
against theophylline was able to discern against the closely
similar molecule, caffeine, that differs from the former by
just a methyl group [30]. The aptamer binds caffeine with a
binding affinity weaker by 10,000 times compared to that of
the theophylline. RNA aptamers were also able to distinguish
between various L and D amino acids [31, 32].
3. Functionalization of Aptamers
for Biodecontamination
Akin to the capture assay application as reviewed by Citartan
et al. [27], the very first step for the application of the
aptamers for the biodecontamination is the immobilization
of the aptamers on the surface of the platforms. To enable
this immobilization, aptamers are first functionalized with
specific functional groups (e.g., thiol, amine, and biotin)
[22, 33]. Interaction of these functional groups with the
functional groups on the surface of the platforms immo-
bilizes the aptamer. Typical functionalization strategy is by
appending amine groups at the aptamer termini (5󸀠 or 3󸀠-
end), which can form peptide bond with the carboxyl groups
on the surface of the platform. The carboxylated surface is
first subjected toN-hydroxysuccinimide (NHS)/1-Ethyl-3-[3-
dimethylaminopropyl] carbodiimide hydrochloride (EDC)
solution activation to form active NHS ester that can react
with the primary amines. Peptide bond-mediated conjuga-
tion of the aptamer on the platform surface was adopted by
Dong Huy et al. [34], in which the anti-17𝛽-estradiol (E2)
aptamers usedwere appendedwith primary amines.The glass
microbeadswere first amino-silanemodified and then treated
with phenylene diisothiocyanate (PDITC) to generate the
isothiocyanate-modified bead, in which the active isothio-
cyanate group can react with the amine-functionalized anti
E2 aptamer. Chen et al. [35] have fabricated a hepatitis C
virus- (HCV-) specific aptamer conjugated with amine to
react with the sepharose 4 Fast Flow (4FF) beads to immobi-
lize the aptamer. The carboxylated-derivative sepharose 4FF
beads, which is 4% highly cross linked spherical sepharose is
activated viaNHS/EDCprior to peptide bond formationwith
the amine-terminated aptamers (Figure 1(a)).
For immobilizing aptamers, nanoparticles are also
employed as the platform, which have more surface area to
volume ratio for the immobilization of aptamers [36]. Hu et
al. [37] have conjugated amine-functionalized aptamer on the
surface of nanoparticles that contain a stable poly (lactic
acid)-polyethylene glycol (PLA-PEG) block copolymer
with a terminal carboxylic acid functional group (PLA-
PEG-COOH) (Figure 1(b)). The carboxylic acid functional
groups form peptide bond with the primary amines.
This immobilizes the aptamers, which were used for the
decontamination of mercury (Hg2+) in vivo. It was also
found out that Metal-Organic Frameworks (MOFs) as the
platform also has high surface area that can accommodate
more aptamers [38]. In one study, MOFs were generated
which comprise Fe3O4 nanoparticles encapsulated with a
polydopamine layer which was then functionalized on the
surface withUiO-66-amine [39]. However, to form a covalent
bond between the amine-conjugated aptamer and the UiO-
66-amine, glutaraldehyde linker was used. The aptamer
was applied for the decontamination of polychlorinated
biphenyls in contaminated soil samples.
Another alternative to conjugate directly to the amine-
conjugated aptamers is to use Cyanogen-bromide (CNBr)
activated crosslinker. CNBr reacts with the hydroxyl group to
generate cyanate esters or imidocarbonates, which can readily
react with primary amines-containing molecules. Madru et
al. [40] covalently immobilized anticocaine aptamer conju-
gated amine on CNBr-activated sepharose. However, there
is growing concern associated with high toxicity of CNBr
and its potentiality as an environmental pollutant [41]. In
addition, surface immobilization of CNBr is time consuming,
which may inactivate the biological activity of aptamer.
Biotin-streptavidin interaction is also used for aptamer
immobilization although the interaction is less strong than
the peptide bond. However, the biotin-streptavidin interac-
tion is rapid and stable over a wide range of pH values and
temperatures [42]. The isoelectric point of streptavidin is 6.8
to 7.5, which minimizes nonspecific adsorption within this
pH range. Biotinylated arsenate (As(V/III)) aptamers func-
tionalized on the surface of streptavidin agarose resin were
used to completely remove As(V/III) in the aqueous solution
[43]. After the completion of the aptamer immobilization
via all the strategies, the unconjugated aptamers should be
removed from the immobilization surface. This is important
as carry-over of these unreacted aptamers into the “target-
capturing process” may result in nonconjugated aptamer-
target formation. If this happens, the decontamination capac-
ity of the immobilized aptamers is reduced.
4. Aptamers as the Pollutant
Absorbent in the Environment
Decontamination process is traditionally achieved by chem-
ical precipitation, ion exchange chromatography, and other
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Figure 1: (a) Schematic representation of the conjugation of the amine-terminated aptamer on the surface of the carboxylated-functionalized
sepharose 4FF beads via NHS/EDC activation [35]. (b) Conjugation of the amine-functionalized aptamer on the surface of nanoparticles that
contain a stable poly (lactic acid)-polyethylene glycol (PLA-PEG) block copolymer with a terminal carboxylic acid functional group (PLA-
PEG-COOH) [37].
methods [9]. However, these are inexpensive and it is not
feasible to reduce their concentrations to the levels as low
as that required by the environmental legislation [44, 45].
A very wise alternative is to use aptamers as the pollutant
absorbents, for binding and removing the environmental
contaminants. Moreover, aptamer-based adsorption does not
result in any secondary pollution as no harmful substances
are produced during the process. One example of aptamer
used in the apta-decontaminant assay is the DNA aptamer
against arsenite [As(III)] and arsenate [As(V)]. Kim et al.
[43] developed a novel apta-decontaminationmethod for the
complete removal of 28.1 to 739.2 𝜇g L−1 As(III) and As(V)
from the groundwater after just 5min of incubation with
its corresponding aptamer. Complete removal of the target
can be achieved in a very short time due to the fast on
and off binding kinetics of the aptamer with the target. In
a similar manner, Hu et al. [46] have developed an apta-
decontamination assay that is able to decontaminate organic
contaminants such as cocaine and diclofenac at ng L−1 levels
in drinking water (Figure 2). In fact, As(III) and As(V)
aptamer column have a better decontamination efficiency
compared with the other filtration technology as demon-
strated by Hsieh et al. [47] on their electro-ultrafiltration
system. The electro-ultrafiltration system has a cut-off value
of 100 kDa and requires the use of electrical voltage of 25V
to achieve As(III) and As(V) decontamination efficiency of
79% in groundwater samples [43]. It is manifested that the
apta-decontamination assay requires no electricity and is
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Figure 2: Illustration of apta-decontamination of cocaine and diclofenac. In this assay, aptamer against cocaine and diclofenac are
immobilized on the resin within a column for the decontamination of cocaine and diclofenac [46].
more specific than the nonspecific nature of the ultrafiltra-
tion system that relies on molecular-weight cut-off value to
decontaminate target.
Ion exchange system is based on the reversible chemical
reactions for removing dissolved ions from solution and
replacing them with other similarly charged ions [48, 49]. It
is timely tomention that, due to higher selectivity and affinity
of the aptamer against the target ion, apta-decontamination
assay could potentially replace or complement ion exchange
system in decontamination. As a proof-of-concept, aptamer
against uranyl ion was used for the decontamination of
uranium. Uranium contaminated drinking water is a com-
mon problem resulted from radioactive disposal waste [50].
Kim et al. [51] have immobilized thiolated aptamer against
uranyl ion on the surface of the sulfo-SMCC (sulfosuccin-
imidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate)-
activated aminopolystyrene resin as the solid support. The
decontamination assay is able to decontaminate 0.63mg of
uranium amidst the presence of the other multiple ions in
the sample [51]. Aptamer as the decontaminating agent is
also able to discriminate between closely similar molecules
and is very selective against the target. Recent study has
shown the RNA aptamer that selectively adsorbs traces
(ng L−1) of microcystin-LR (MC-LR) in drinking water [52],
discriminating againstmicrocystin-RR,microcystin-LW, and
nodularin which are cyclic pentapeptides that have a similar
structure with MC-LR. This aptamer could be used as the
decontaminating agent to remove MC-LR. MC-LR is a
potential carcinogen for animals and humans that is present
in aquatic environment [53, 54].
Isolation of aptamers against bacterial surface proteins
or against the whole-cell [55] permits their application in
removing bacteria from the environment. Song et al. [56]
used three different aptamers selected using a bacterial
cell–SELEX that have different affinities and target different
proteins on surface of Escherichia coli (E. coli). The target
proteins may be components such as Lipopolysaccharide
(LPS), outer membrane proteins, and flagella, which must
be confirmed by aptamer-facilitated biomarker discovery
(AptaBiD) [57].These amino-modified aptamerswere immo-
bilized on the surface of TiO2 for targeted and enhanced
disinfection of E. coli (Figure 3). The target E. coli was
approximately 99% inactivated under UV irradiation in 30
min.The assay was also specific and selective, as it inactivates
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Figure 3: Schematic diagram of apta-decontamination of bacteria.
Three aptamers specific against three different bacterial surface
proteins were immobilized on surface of TiO2 to specifically capture
𝐸. coli, which is then deactivated under UV irradiation [56].
only E. coli in the presence of a mixed culture (E. coli and
Staphylococcus epidermidis). Besides bacteria, aptamers were
also used to remove contaminating bacteria toxins from soil,
food, and water environment [9, 58].
In general, a cause for concern is the difference in the
ionic strength/pH of the aqueous environmental target from
the optimal buffer used for the aptamer interaction that
could debilitate its binding affinity. To address this problem,
aptamers should be placed in a distinct compartment to
thwart them from being affected by surroundings that will
undermine their binding capacity. As such, liposomes that
contain the aptamer binding buffer could be possibly used
as the holding moiety for aptamers. Kim et al. [59] have
constructed biocomposite material that comprise liposome
that contains aptamers dissolved in the binding buffer for the
selective and simultaneous decontamination of E2, bisphenol
A (BPA), and oxytetracycline from the contaminated water
within 30 minutes (Figure 4). The capturing efficiency is
higher (more than 80%) when liposomes are used as the
holding moiety as compared to the DNA aptamers in water.
The cases enumerated are sufficient to imply that the apta-
decontamination assay could potentially replace or comple-
ment the current existing strategies in decontaminating small
molecules in the environment.
5. Apta-Decontamination Assay
on Food Sample
Besides, majorly in the environment, the capturing capacities
of the aptamers are also exploited to remove contami-
nants from food sample. Most of the apta-decontamination
assays on food sample reported so far revolve only around
ochratoxin A (OTA) aptamer, isolated by Cruz-Aguado and
Penner [60], with the estimated dissociation constant (𝐾𝑑) of
360 nM.They have developed the first aptamer-based affinity
column for the concentration and decontamination of OTA.
TheOTA aptamers were conjugated to agarose resin andwere
packed into a pipette tip, which was used as the column. The
performance of the affinity column-functionalized aptamer
was first tested with a buffer spiked with OTA, whereby more
than 97% of OTA was removed from 1mL of a 100 nM OTA
solution. Subsequently, the apta-decontamination assay of
OTA was further coupled with fluorescence detection for
the better monitoring of the OTA removal. In this study,
Yang et al. [61] developed an aptamer affinity column with
ultrahigh performance liquid chromatography coupled with
fluorescence detection to remove OTA from ginger powder.
The amount of OTA removed from the ginger powder ranged
from 1.51 to 4.31 𝜇g kg−1, which was lower than the European
Union regulatory limits. Average recovery of 85.36–96.83%
was acquired for blank samples spiked with OTA at 5, 15, and
45 𝜇g kg−1.
The OTA removal was also facilitated with the use of
magnetic field mediated by magnetic nanoparticles, which
can offer higher capturing efficiency with shorter diffusion
time. Wu et al. [62] have immobilized OTA aptamers on the
surface of the magnetic nanospheres and have developed a
magnetic solid phase extraction procedure to remove OTA
from the food samples. The assay developed consists of
high performance liquid chromatography separation and a
fluorescence detection (HPLC-FD) system [62].The clean-up
of the OTA was facilitated by magnetic field and the removal
of OTA was monitored by HPLC-FD. With 2.5–50 𝜇g kg−1
of OTA spiked in different samples of cereals products and
wheat flour spiked, the recoveries varied from 67 to 90%.
The apta-decontamination assay showed a high selectivity in
comparison to a conventional hydrophobic sorbent, with a
good extraction recovery. However, as observed in the case
study by Schax et al. [10], using OTA, the binding capacity of
the aptamer against the corresponding targets is diminished
in complex sample. Thus this strongly suggests that during
in vitro selection, complex media could be used as the SELEX
binding buffer.The complexmedia, which are optimal for the
aptamer performance, will ensure that the aptamer binding
is retained during the decontamination process. Moreover,
Sefah et al. [63] have shown that the in vitro selection carried
out in culture media Dulbecco’s phosphate-buffered saline as
the SELEX binding buffer is still be able to produce aptamers
that bind target in the similar buffer.
Apta-decontamination system enables specific extrac-
tion of toxins or natural compounds from turbid matrices
in a one-step procedure. Rouah-Martin et al. [64] have
developed apta-decontamination of ergot alkaloids (causing
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Figure 4: Illustration of apta-decontamination using liposome containing aptamer. Liposomes that contain the aptamer binding buffer also
comprise aptamers that are specific against 17𝛽-estradiol (E2), bisphenol A, and oxytetracycline.These aptamers bind the contaminants (17𝛽-
estradiol (E2), bisphenol A, and oxytetracycline) and remove them from the contaminated water source [59].
severe poisoning known as ergotism), using DNA aptamer-
based ergot alkaloids immobilized on silica for specific
solid phase extraction system. The assay enables specific
extraction of ergot alkaloids from a contaminated rye feed
sample prior to the analysis of the extract using liquid chro-
matography quadrupole-time-of-flight mass spectrometry.
The success manifested by the OTA and ergot alkaloids
aptamers may further fuel the isolation and subsequent
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application of the aptamers against contaminants in the food
product.
6. Aptamers as the Potential In Vivo
Decontamination Agent
High specificity conferred by aptamers with minimal off-
target binding accounts for its wide application in the fields
of drug delivery, therapeutic agent, molecular biosensing,
and biomimetic engineering [17, 65–70]. This also strongly
insinuates that aptamers can also be potentially used to
decontaminate contaminants in vivo [27, 35].
Aptamer-based decontamination assay is used to selec-
tively capture and detoxify infectious agents. In one study,
Chen et al.[35] used HCV-specific single-stranded DNA
aptamers to decontaminate approximately 80% of the
HCV from human plasma samples. This novel apta-
decontamination procedure could effectively remove HCV
particles and likely to serve as a novel therapy option for
HCV. Proske et al. [71] have used nuclease-resistant 2󸀠-
amino-2󸀠-deoxypyrimidine-modified RNA aptamers (DP7)
that recognize a peptide comprising amino acid residues
(90–129) human prion protein with high specificity. This
particular region is important for the conversion of PrP(C)
into its pathogenic isoform PrP(Sc). This aptamer results
in the reduction of PrP(Sc) accumulation in prion-infected
cells. The DP7 aptamer may open the door towards using
aptamers as a rational therapeutic of transmissible spongi-
form encephalopathies.
The high stability and less immunogenicity associated
with aptamers potentiate aptamers for the selective capturing
and eliminating a circulating tumor cells. Li et al. [67] pre-
sented a study that makes use of hydrogel functionalized with
two layers with the top one containing DNA aptamer specific
against humanprecursor T-cell acute lymphoblastic leukemia
cells (CCRF-CEM), while the bottom one contains double-
stranded DNA as the “affinity tag” for the intercalation of
doxorubicin to eradicate target circulating tumor cells. The
aptamer on the top hydrogel layer was able to capture CCRF-
CEM cells with high efficiency and specificity, while the dox-
orubicin sequestered at the bottom is released to kill tumor
cells. Moreover, Li et al. [72] developed an endonuclease-
responsive circulating tumor cells aptamer that was function-
alized on hydrogels for the specific catch and nondestructive
release of rare circulating tumor cells. The aptamer was
hybridized to another sequence that is immobilized on the
surface of the hydrogel. Both the sequence immobilized on
the surface of the hydrogel and the aptamer sequence harbour
restriction endonuclease cleavage site, targeted by BamHI.
The cells captured by the aptamers will be released after the
cleavage of the restriction sites (Figure 5). Specificity of the
assay is also substantiated as the assay developed showed
binding of CCRF-CEM cells rather than Ramos cells on the
hydrogel surface.The capture and release of circulating tumor
cells can be used for decontamination and for the detailed
analysis of circulating tumor cell properties [72]. Reports
found out that chemotherapeutic agents such as cisplatin or
5FU increase the amount of heat shock protein 70 (HSP70)
exosomes, which then activates myeloid-derived suppressive
Hybridize
Catch
Release
Target cells
Restriction endonuclease
Sequence B (aptamer)
Sequence A
Hydrogel coating
Figure 5: Schematic diagram of an application of aptamer in
capturing and releasing tumor cells. Sequence immobilized on the
surface of the hydrogel forms a duplex with an aptamer sequence.
Cleavage of the restriction sites on the aptamer (sequence B) and
the immobilized sequence (sequence A) releases the target cells.
Endonuclease cleaves the phosphodiester bond within the aptamer,
resulting in the loss of its anchoring to the target cells. Subsequently,
the target cells are dissociated from the aptamer and released [72].
cells (MDSCs) obstructing the development of an antitumor
immune response [73]. Exosomes through HSP70 expressed
in their membrane then interact with the toll-like receptor
2 (TLR2) to activate MDSCs. Gobbo et al. [74] reported the
capturing application of the peptide aptamer that binds to
the extracellular domain of membrane HSP70 and to capture
HSP70 exosomes from cancer patient samples. The aptamer
is able to block the interaction between HSP70 and TLR2,
suppressing the activation of the MDSCs. In fact, aptamers
can be a promising class of molecules for decontaminating
contaminants in vivo owing to high selectivity and their
superior characteristics of high cell penetration capacity.
7. Reusability of Aptamers as
the Decontaminating Agents
An ideal criterion of a decontamination assay is reusability,
which can be conveyed by aptamers that have reversible
denaturation property [75, 76]. Reusability of the aptamer
refers to the repetitive usage of aptamers in binding and
eluting their corresponding targets with minimal loss of cap-
turing efficiency. Aptamers can be denatured and renatured
to their original conformations by changing the temperature
and pH. Recently, Hu et al. [46] appraised the reusability of an
aptamer-based column in removing cocaine and diclofenac
from the drinking water. Decontamination capacities of the
aptamers were evaluated before and after 30 days at 4∘C
and were found to decrease by only 1.2–4.7%. Moreover, the
regeneration of the aptamer-based column was achieved by
simple washing with pure water at a rate of 10mLmin−1 at
50∘C for 5min.The decontamination capacity of the aptamer
column decreased approximately by 10% after 10 regeneration
cycles, corroborating that covalent binding between aptamers
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Figure 6: Schematic representation of the reusability of aptamer-
based hydrogel scavenger in apta-decontamination of three pol-
lutants. Aptamers are immobilized on the surface of the Fe3O4-
Ag Janus-type hybrid nanoparticles encapsulated within a 3D
porous structure of hydrogel. The targets (heavy metal ions, organic
pollutants, and pathogens in drinking water) are captured by the
aptamers. Aptamers are reused/regenerated by changes in the pH
and the aptamers can be reused for the subsequent capture assay
[77].
and CNBr-sepharose is stable despite using hot water. Using
a similar approach of regeneration, Hu et al. [52] have
“regenerated” MC-LR aptamer functionalized on surface
of RNA–graphene oxide with hot water and their apta-
decontamination capacity reduced by about less than 10%
after 5 cycles. Schax and coworker [10] tested the reusability of
OTA aptamer-based column for 4 additional cycles of decon-
tamination within 20 days. In between the decontamination
cycles, the aptamer-based column was washed with binding
buffer to ensure refolding of the aptamer followed by storage
at 4∘C in binding buffer. The aptamer remained stable for a
period of 20 days, and the amount of OTA obtained did not
change profoundly, between 84 and 94% for all the cycles,
with elution efficiency between 71 and 84%. Wang et al. [77]
reported 𝑎 hydrogel scavenger containing aptamers immobi-
lized on Fe3O4-Silver (Ag) Janus-type hybrid nanoparticles
encapsulated within a 3D porous structure of hydrogel for
high efficiency of simultaneous decontamination of Hg2+
(99.96%), BPA (98.9%), and E. coli (100%) in drinking water
as showed in Figure 6. Regeneration is achieved based on
the changes in the pH, whereby the hydrogel scavenger
was washed with HCl (pH 1) and water three times. In
almost all the cases mentioned, the efficiency of the aptamers
remains the same after several cycles of decontamination,
which demonstrates the excellent reusability property of the
aptamer. Another elution strategy is based on the usage of
the chelating agent, which chelates the divalent ions that are
important for the binding affinity of the aptamer against the
target. In the presence of the chelating agent that chelates
the divalent ion, the target is released from the aptamer.
This is because the aptamer is unable to retain the structural
conformation without the presence of the divalent ion. In
one surface plasmon resonance analysis that aims to look at
the significance of the calcium (Ca2+) ion for the interaction
between the RNA aptamer and its corresponding target
human immunoglobulin (IgG1), addition of ethylenediamine
tetra-acetic acid (EDTA), which chelates the Ca2+, results in
the loss of the binding affinity between these two molecules.
However, the affinity is regained upon the addition of the
ion. It can be surmised that the chelating agents can be used
for the elution of the target [78]. Integration of the aptamer
into the decontamination assay can immensely save cost.
The overall cost of manufacturing aptamer is plummeting,
which is also influenced largely by the increasing demand
for oligonucleotides that accounts for the reduction in the
cost of nucleotide phosphoramidites. For one gram of DNA
phosphoramidites, the estimated cost is less than US$3, while
that for per gram of 2󸀠-fluoro, 2󸀠-ribo, and 2󸀠-O-methyl RNA
phosphoramidites costs less than US$20 [79].
8. Chemical Modifications for the Enhanced
Stability of the Aptamer
During the apta-decontamination process, the most promi-
nent challenge is to stabilize or protect the aptamers (espe-
cially RNA aptamers) from the degradation action of the
nucleases that are present in the environmental soil andwater.
Stability can be achieved via modification of the aptamer
following isolation by SELEX. However, due diligence should
be practiced as POST-SELEX modification may impair the
binding affinity of the aptamer against the target [80]. Hence,
it is desirable to incorporate the chemical modification into
the library used for the in vitro isolation of the aptamers.
Modification includes the addition of cap at the 3󸀠- and/or
5󸀠- ends to occlude the exonuclease degradation action [81].
Stability of the aptamers can also be enhanced by using
phosphorothioate nucleotides [82]. Another modification is
Locked nucleic acids (LNAs), whereby the 2󸀠-O is linked to
the 4󸀠-C of the ribose via a methylene bridge, giving rise
to 3󸀠-endo conformation that is stable against the action
of nucleases [83, 84]. A highly nuclease-resistant aptamer,
Spiegelmer, a mirror-image aptamer built from nucleotides
of the nonnatural L-chirality, can be a perfect candidate for
decontamination. As these L-aptamers are mirror images of
the natural D-aptamer counterpart of the same sequence,
the former is unrecognized by the stereoselective nucleases.
Consequently, spiegelmers are highly resistant to the action of
nucleases [85]. Modification is also achievable by substituting
hydroxyl group at the 2󸀠-position of the ribose sugar with the
amino (NH2), fluoro (F), alkyl, and thio groups [86].
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9. Point-of-Care Aptamer-Based
Decontamination Assay
The diagnostic technology has moved into another dimen-
sion, whereby the diagnostic can be performed anywhere
with a fast turnaround time that enables quicker treat-
ment, known as the point-of-care testing [87]. Analogous
to a point-of-care diagnostic assay, an apta-decontamination
assay should also be developed on a similar basis, so that
the decontamination can be carried out anytime that could
permit instant decision-making. Fueled by the need to avoid
health hazards, ecosystem, food, and water contaminated
by a variety of microbial pathogens, toxins, heavy metals,
organic pollutants, and adulterants should be subjected to
decontamination before reaching consumers [88]. The ideal
point-of-care aptamer-based decontaminating device should
be of low power, low cost, reusable, provide durability,
and have a high apta-decontamination capacity without any
secondary pollution in purifying environmental pollutants.
A point-of-care assay developed byWang et al. [77] exhibited
the ideal application of a novel apta-decontamination, which
consists of an empty filter unit of a commercially available
water purifier. The water purifier is packed with hydrogel
scavenger that accommodates multiple aptamers that can
capture pollutants.The hydrogel scavenger also holds Fe3O4-
Ag Janus nanoparticles functionalizedwithmultiple aptamers
to remove metal ions, organic pollutants, and pathogens
simultaneously. This apta-decontaminant showed an out-
standing performance in reducing Hg2+ concentration from
1 ppm to levels lower than 1.1 ppb and BPA from 60 ppm
to level smaller than 0.8 ppm and can effectively destroy
more than 99.998% of E. coli simultaneously. This aptamer-
based decontamination device can remove three different
elements simultaneously, suggesting that multiple aptamers
can be used in future for the removal of a myriad of major
environmental contaminants. The study carried out could
provide an impetus to expedite the development of point-of-
care apta-decontaminating device that is mobile and with a
platform that is immobilized with multiple aptamers that are
specific against different targets.
10. Conclusion and Future Perspective
Despite great promise, there are major barriers that must
be transcended to use aptamers as decontamination agents.
Biostability of aptamers is one of the concerns that currently
limits the application aptamers as decontamination agents
in the real world [89]. Therefore, to generate aptamers with
proved biostability, a direct evolution of a nuclease-resistant
sequences from a library of different chemical substituents
should be carried out [90, 91]. Another critical factor that
must be heeded is the compatibility of the aptamer with the
environmental condition which the aptamer is subjected to
during decontamination process.Metal cation concentration,
buffer conditions, and temperature are themain elements that
influence the stability and affinity of the aptamers [92, 93].
The best approach is to mimic the actual environmental
condition by which the aptamer is exposed to at the point
of capturing process in the SELEX process itself. As such,
aptamers that can optimally perform during the capture
process can be successfully isolated [94].
Aptamers are quite flexible in the functionalization, ther-
modynamically stable, and able to bind target within a short
period of time and are also stable despite repetitive usage.
Endowed with these excellent properties, aptamers have
“fared well” in decontaminating environment, food sample,
and removing infectious agents, which is also supported
by the availability of aptamers against a number of small
molecular contaminants. Thus, it is felicitous to say that the
apta-decontaminating assay should not merely be applicable
for decontamination, but also be focused towards capturing
and removing hazardous agents. One case study is exhibited
by Ranjbar and Hafezi-Moghadam [95] who have designed a
MPT64 antibody aptamer-based DNA nanorobot. The lock
is constituted by the duplex formation between the aptamer
sequence and the complementary strand. In the presence of
the target, the aptamer strand binds to it, opening up the
lock, releasing the drug molecules from the nanorobot that
can interact with the bacterial surface protein. It is worth
noting that DNA origami structure, which is a long single-
stranded scaffold that could be moulded into any intended
configurations using short ssDNA as the connectors [96, 97],
could serve as a powerful smart material in the future that
could assist the aptamers to capture and eradicate bacteria
as well as virus-infecting eukaryotic cells. Inspiration can
also be derived from Douglas et al. [98] who have fabricated
DNA nanorobot by using DNA origami technology that is
programmed to independently recognize target defected cells
and deliver payloads. Aptamers specific against any targets
can be infiltrated into the DNA origami and the whole
ensemble can be adopted for targeted elimination of the
bacteria. The application of DNA origami can be extended
towards the simultaneous decontamination of a panel of
contaminants in water via the usage of the corresponding
specific aptamers.Multiple aptamers can be conjugated to the
ssDNA constituents of the DNA origami and binding against
their cognate targets may induce conformational change that
can facilitate capturing and removal of the target.
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